GLS-012 is under clinical development by Guangzhou Gloria Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GLS-012’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GLS-012 overview
GLS-012 is under development for the treatment of malignant tumors such as advanced melanoma, solid tumor and non-small cell lung cancer. It is administered through intravenous route as infusion. The drug candidate acts by targeting lymphocyte activation gene 3 (LAG3).
Guangzhou Gloria Biosciences overview
Guangzhou Gloria Biosciences is a professional biological research and development company. The company focuses on the development of products in the field of tumor immunotherapy. Guangzhou Gloria Biosciences product, sepalimab, is a fully human anti-PD-1 monoclonal antibody used for the treatment of relapsed or refractory classical Hodgkin’s lymphoma. The company’s products are used in the healthcare industry, specifically in the treatment of various types of cancer. It operates with an additional office in Beijing, China. Guangzhou Gloria Biosciences is headquartered in Guangzhou, Guangdong, China.
For a complete picture of GLS-012’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.